The FDA must have agreed to three-months double-blinded, plus open-label extension.
That is quicker and , in many ways, better than a six-month double-blinded trial. Including better for the kids.
It's a significant vote of confidence.
Ann: Plans for Phase 3 trial in Rett syndrome, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.240(1.56%) |
Mkt cap ! $1.881B | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.45 | $15.03 | $5.415M | 355.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1050 | $15.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.17 | 473 | 8 |
View Market Depth
| Last trade - 15.29pm 21/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |